Kefir Improves The Efficacy And Tolerability Of Triple Therapy In Eradicating Helicobacter Pylori
Notes for this study:
||When kefir was used as an adjunct to the standard pharmaceutical therapy for H. pylori infections, the kefir+standard group had less nausea (relative risk = 0.47)
|Number of Subjects
||18-29, 30-44, 45-64, 65+
Helicobacter pylori (H. pylori) infection is a common cause of ulcers and chronic gastritis, making H. pylori elimination therapy a cornerstone of treatment for these conditions. Elimination is via "triple therapy" - treatment with a _proton pump inhibitor_ (PPI) and two antibiotics. This RCT of 82 patients of Turkish descent tested whether adding kefir consumption would improve the efficacy and tolerability of triple therapy. The patients were given a two-week course of lansoprazole (PPI), amoxicillin, and clarithromycin, plus either 250 mL of kefir twice daily (46 patients) or a milk placebo (36 patients). The patients given kefir had a significantly higher H. pylori eradication rate (78% vs 50%) 45 days after starting treatment, and reported significantly less occurrence of the adverse effects diarrhea, headache, nausea, and abdominal pain at a day-15 follow-up visit.
Funding issues for this study:
The kefir used in this study was specially prepared for it by Turkish kefir manufacturer EKER. Its microbial composition isn't addressed in the study.
The kefir was provided free of charge by EKER.